(1S,4S)-2,5-Diazabicyclo[2.2.1]heptane Dihydrobromide acts as a reagent for the synthesis and characterization of new piperazine-type inhibitors for mitochondrial ubiquinone reductase, preparation of heterocyclic compounds as chemokine receptor inhibitors useful in treatment of CXCR4-mediated diseases.